

# 1 **MUTATE: A Human Genetic Atlas of Multi-organ AI** 2 **Endophenotypes using GWAS Summary Statistics**

3  
4 Aleix Boquet-Pujadas<sup>1</sup>, Jian Zeng<sup>2</sup>, Ye Ella Tian<sup>3</sup>, Zhijian Yang<sup>4</sup>, Li Shen<sup>5</sup>, Andrew Zalesky<sup>3</sup>,  
5 Christos Davatzikos<sup>6</sup>, the MULTI consortium<sup>#</sup>, Junhao Wen<sup>1,7,8,9\*</sup>,

6  
7 <sup>1</sup>Laboratory of AI and Biomedical Science (LABS), Columbia University, New York, NY, USA

8 <sup>2</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia

9 <sup>3</sup>Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of  
10 Melbourne, Melbourne, Victoria, Australia

11 <sup>4</sup>GE Healthcare, Bellevue, WA, USA

12 <sup>5</sup>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of  
13 Medicine, Philadelphia, PA, USA

14 <sup>6</sup>Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated  
15 Diagnostics (AI<sup>2</sup>D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

16 <sup>7</sup>New York Genome Center (NYGC), New York, NY, USA

17 <sup>8</sup>Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID), Department of Radiology,  
18 Columbia University, New York, NY, USA

19 <sup>9</sup>Data Science Institute (DSI), Columbia University, New York, NY, USA

20

21

22 \*Corresponding authors:

23 Junhao Wen, [junhao.wen89@gmail.com](mailto:junhao.wen89@gmail.com)

24 622 W 168th St, New York, NY 10032

25 # Consortium representative: Dr. Junhao Wen

26

27 **Keywords**

28 Multi-organ AI endophenotypes, genetic correlation, Mendelian randomization, polygenic risk  
29 score

## 30 **Abstract**

31 Artificial intelligence (AI) has been increasingly integrated into imaging genetics to provide  
32 intermediate phenotypes (i.e., endophenotypes) that bridge the genetics and clinical  
33 manifestations of human disease. However, the genetic architecture of these AI endophenotypes  
34 remains largely unexplored in the context of human multi-organ system diseases. Using publicly  
35 available GWAS summary statistics from the UK Biobank, FinnGen, and the Psychiatric  
36 Genomics Consortium, we comprehensively depicted the genetic architecture of 2024 multi-  
37 organ AI endophenotypes (MAEs). We comparatively assessed the SNP-based heritability,  
38 polygenicity, and natural selection signatures of 2024 MAEs using methods commonly used in  
39 the field. Genetic correlation and Mendelian randomization analyses reveal both within-organ  
40 relationships and cross-organ interconnections. Bi-directional causal relationships were  
41 established between chronic human diseases and MAEs across multiple organ systems, including  
42 Alzheimer's disease for the brain, diabetes for the metabolic system, asthma for the pulmonary  
43 system, and hypertension for the cardiovascular system. Finally, we derived polygenic risk  
44 scores for the 2024 MAEs for individuals not used to calculate MAEs and returned these to the  
45 UK Biobank. Our findings underscore the promise of the MAEs as new instruments to  
46 ameliorate overall human health. All results are encapsulated into the MUTATE genetic atlas  
47 and are publicly available at <https://labs-laboratory.com/mutate>.

## 48 Introduction

49 Multi-organ research<sup>1-9,10,11</sup> represents a pivotal frontier in advancing our understanding of  
50 human aging and disease. In particular, integrating artificial intelligence (AI) into multi-organ  
51 imaging genetics<sup>1,4,12,3</sup> has emerged as a novel approach, offering potential promise in advancing  
52 precision medicine<sup>13</sup>. This integration introduces a new array of endophenotypes<sup>14,15</sup>, serving as  
53 intermediate, often quantitative, phenotypes, potentially reshaping how we perceive and  
54 approach medical AI<sup>16</sup> in imaging and genetic research.


55 In recent years, three primary catalysts have significantly advanced the field of genetics.  
56 The first pivotal factor stems from the extensive collaborative efforts in consolidating large-scale  
57 multi-omics datasets, which has endowed researchers with unprecedented statistical power  
58 previously inaccessible. As an illustration, the UK Biobank (UKBB) study<sup>17</sup> stands out for its  
59 comprehensive collection of multi-organ imaging<sup>18</sup>, genetics<sup>19</sup>, and proteomics<sup>20,21</sup> data within  
60 the United Kingdom. Similarly, the FinnGen study<sup>22</sup>, conducted in Finland, has amassed  
61 extensive clinical and genetic data. Secondly, efforts toward open science have propelled the  
62 field, especially emphasizing the significance of publicly available resources, such as genome-  
63 wide association study (GWAS) summary statistics and widespread scientific dissemination.  
64 Notably, the FinnGen study and Psychiatric Genomics Consortium (PGC<sup>23</sup>) have publicly made  
65 all the GWAS summary statistics accessible<sup>22</sup>. Public GWAS platforms such as the GWAS  
66 Catalog<sup>24</sup>, OpenGWAS<sup>25</sup>, and GWAS ATLAS<sup>26</sup> have consolidated and harmonized vast GWAS  
67 datasets, rendering them suitable for subsequent genetic analyses. Likewise, such good practice  
68 was also employed in the newly burgeoning field of brain imaging genetics<sup>27</sup>, including the  
69 BIG40 (<https://open.win.ox.ac.uk/ukbiobank/big40/>), the BIG-KP (<https://bigkp.org/>),  
70 BRIDGEPORT (<https://labs-laboratory.com/bridgeport>), and MEDICINE ([https://labs-](https://labs-laboratory.com/medicine)  
71 [laboratory.com/medicine](https://labs-laboratory.com/medicine)) knowledge portals. Finally, advanced computational genomics  
72 statistical methods using solely GWAS summary statistics, along with sufficient linkage  
73 disequilibrium information, have been developed, presenting an unparalleled chance to  
74 comprehend the genetic architecture of highly polygenic disease traits. For example, LDSC<sup>28</sup> has  
75 been extensively utilized to estimate single-nucleotide polymorphism (SNP)-based heritability  
76 and genetic correlations. Mendelian randomization<sup>29</sup> is a statistical method to dissect associations  
77 further, probing potential causal relationships among these complex human disease traits,  
78 although these methods often rely on several sensitive model assumptions<sup>30</sup>.

79 Despite these advancements, the intricate genetic foundation shaping these AI  
80 endophenotypes in the context of pleiotropic human disease endpoints (DE) within multi-organ  
81 systems remains largely uncharted. We previously applied AI to imaging genetic data and  
82 derived 2024 multi-organ AI endophenotypes (MAE). These encompassed 2003 multi-scale  
83 brain patterns of structural covariance (PSC) networks generated through a deep learning-  
84 analogy non-negative matrix factorization method<sup>12</sup> (visualization for C32\_1 encompassing deep  
85 subcortical structures: [https://labs-laboratory.com/bridgeport/MuSIC/C32\\_1](https://labs-laboratory.com/bridgeport/MuSIC/C32_1)), 9 dimensional  
86 neuroimaging endophenotypes (DNE) quantifying neuroanatomical heterogeneity (also known as  
87 disease subtype) within 4 common brain diseases<sup>4</sup>, and 12 biological age gap (BAG) assessing  
88 the individual deviation in typical aging (i.e., acceleration or deceleration from the chronological  
89 age) across 9 human organ systems<sup>1,3</sup> (**Supplementary eTable 1a**). The 2,024 MAEs were  
90 generated using data-driven AI and machine learning methods, distinguishing them from  
91 conventional imaging phenotypes (e.g., brain volume used in Elliott et al.<sup>19</sup>) and clinical  
92 diagnoses (e.g., binary Alzheimer's disease (AD) diagnosis). For instance, we applied our  
93 Surreal-GAN model<sup>31</sup> to neuroimaging data to derive two AD DNEs that capture the

94 neuroanatomical heterogeneity of AD<sup>32</sup>. In contrast, traditional AD or AD-by-proxy approaches  
95 do not account for this heterogeneity and led to potential bias<sup>33</sup>, either inherently or in  
96 downstream GWAS analyses. To contribute to open science<sup>34</sup>, we made all the GWAS summary  
97 statistics derived from UKBB data publicly available at the MEDICINE knowledge portal:  
98 <https://labs-laboratory.com/medicine>. In addition, FinnGen analyzed genetic data for 2269 binary  
99 and 3 quantitative DEs from 377,277 individuals and 20,175,454 variants. They made these  
100 massive GWAS summary statistics publicly available to the community at  
101 <https://finngen.gitbook.io/documentation/> (**Supplementary eTable 1b**). Finally, PGC  
102 consolidated GWAS results focused on neurological disorders worldwide and made the GWAS  
103 summary statistics accessible to the research community (<https://pgc.unc.edu/>, **Supplementary**  
104 **eTable 1c**) (**Fig. 1**).

105 This study harnesses the extensive GWAS summary resources made publicly available  
106 by us on behalf of UKBB, FinnGen, and PGC (**Method 1**), along with the utilization of several  
107 advanced computational genomics statistical methods (refer to **Code Availability**), to thoroughly  
108 depict the genetic architecture of the 2024 MAEs (**Method 2**) and 525 DEs (>5000 cases) in the  
109 context of multi-organ investigations. Importantly, our previous research explored the genetic  
110 foundation of the 2024 MAEs but did not systematically encompass the FinnGen or PGC data.  
111 Specifically, we included 521 DEs released by the FinnGen study, accessible at  
112 <https://finngen.gitbook.io/documentation/v/r9/>, and 4 brain DEs (Alzheimer's disease (AD),  
113 Attention-deficit/hyperactivity disorder (ADHD), bipolar disorder (BIP), and schizophrenia  
114 (SCZ)) from PGC (<https://pgc.unc.edu/>). This study expanded on this by systematically  
115 benchmarking the genetic analyses and comprehensively comparing various statistical  
116 methodologies<sup>28,30,35-41</sup> (**Method 3**). Specifically, we aimed to compute the SNP-based  
117 heritability ( $h_{SNP}^2$ ), polygenicity ( $\pi$ ), the relationship between SNP effect size and minor allele  
118 frequency ( $S$ : signature of natural selection, genetic correlation ( $r_g$ ), causality, and polygenic risk  
119 score (PRS) between the 2024 MAEs and 525 DEs. These findings were encapsulated within the  
120 MUTATE (MUITi-organ AI endophenoTypeE) genetic atlas, which is publicly available at  
121 <https://labs-laboratory.com/mutate>.

122



123  
124  
125  
126  
127  
128  
129  
130

### Figure 1: The 2024 MAEs and 525 DEs

Using GWAS summary data from the UK Biobank, we generated 2024 MAEs (<https://labs-laboratory.com/medicine/>; <https://labs-laboratory.com/bridgeport>). Additionally, we harmonized GWAS summary data from FinnGen ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)) and PGC (<https://pgc.unc.edu/for-researchers/download-results/>) to incorporate 525 disease endpoints (DEs). All analyses in this study were conducted exclusively using GWAS summary data from these three public resources.

## 131 **Materials and methods**

### 132 **Method 1: The MULTI consortium**

133 The MULTI consortium is an ongoing initiative to integrate and consolidate multi-organ and  
134 multi-omics biomedical data, including imaging, genetics, and proteomics. Building on existing  
135 consortia and studies, such as those listed below, MULTI aims to curate and harmonize the data  
136 to model human aging and disease across the lifespan at individual and summary levels. The  
137 present study solely utilized GWAS summary statistics; no individual-level data were used. We  
138 downloaded the GWAS summary statistics from three web portals for the 2024 MAEs, 521 DEs  
139 from FinnGen and 4 DEs from PGC.

140

### 141 **UKBB**

142 UKBB is a population-based study of approximately 500,000 people recruited from the United  
143 Kingdom between 2006 and 2010. The UKBB study has ethical approval, and the ethics  
144 committee is detailed here: [https://www.ukbiobank.ac.uk/learn-more-about-uk-  
145 biobank/governance/ethics-advisory-committee](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee).

146 The GWAS summary statistics for all the 2024 MAEs are publicly available at the  
147 MEDICINE knowledge portal: <https://labs-laboratory.com/medicine>, which focuses on  
148 disseminating scientific findings on imaging genetics and AI methods in multi-organ science.  
149 Specifically, among the 2024 MAEs, 2003 PSCs – at varying scales from C32 to C1024 – were  
150 structural covariance networks derived via the sopNMF method<sup>12</sup>. 9 DNEs<sup>4</sup> captured the  
151 neuroanatomical heterogeneity of four brain diseases (AD1-2, ASD1-3, LLD1-2, and SCZ1-2)  
152 using semi-supervised clustering or representation learning methods. 12 multi-organ BAGs (GM,  
153 WM, FC<sup>3</sup>, multimodal brain BAGs, cardiovascular BAG, eye BAG, hepatic BAG, immune  
154 BAG, musculoskeletal BAG, metabolic BAG, pulmonary BAG, and renal BAG<sup>42</sup>) were derived  
155 from various machine learning models to quantify the individual-level deviation from typical  
156 brain aging due to various pathological effects. Detailed AI methodologies are presented in  
157 **Method 2** for the MAEs, DNEs, and BAGs. All GWASs were performed within European  
158 ancestries and using the GRCh37 human genome assembly; the GWAS model (PLINK<sup>43</sup> for  
159 linear model and fastGWA<sup>44</sup> for linear mixed-effect model), sample sizes, and covariates  
160 included are detailed in the original papers and also in **Supplementary eTable 1a**.

161

### 162 **FinnGen**

163 The FinnGen<sup>22</sup> study is a research project based in Finland that explores combined genetics and  
164 health registry data to understand the underlying causes and mechanisms behind various disease  
165 endpoints. It particularly emphasizes the genetic basis of diseases in the Finnish population  
166 (>500,000) by conducting extensive GWAS and analyzing large-scale genomic data in  
167 collaboration with multiple research institutions and organizations. FinnGen has generously  
168 made their GWAS results publicly available to the community for research purposes  
169 ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)).

170 The present study used the GWAS summary statistics version R9 released to the public  
171 on May 11, 2022, after harmonization by the consortium. In the R9 release, FinnGen analyzed  
172 2269 binary and 3 quantitative endpoints from 377,277 individuals and 20,175,454 variants.  
173 Regenie<sup>45</sup> was used to run the GWAS models, including sex, age, 10 PCs, and genotyping batch  
174 as covariates. Genotype imputation was done with the population-specific SISu v4.0 reference  
175 panel. In our analysis, we concentrated solely on binary DEs with case numbers exceeding 5000

176 to ensure adequate statistical power, given the highly imbalanced case/control ratios. As the  
177 released data were based on the GRCh38 human genome assembly, we lifted the GWAS  
178 summary statistics to the GRCh37 version for all genetic analyses. **Supplementary eTable 1b**  
179 details the included 521 DEs. More details can be found at the FinnGen website:  
180 <https://finngen.gitbook.io/documentation/v/r9/>.

## 181 182 **Psychiatric Genomics Consortium**

183 PGC<sup>23</sup> is an international coalition of researchers exploring the genetic underpinnings of  
184 psychiatric disorders and beyond. This collaborative effort unites scientists globally to examine  
185 and decipher extensive genomic datasets concerning various brain diseases. The primary goal of  
186 PGC involves uncovering and comprehending the genetic elements that contribute to various  
187 psychiatric disorders, such as schizophrenia, bipolar disorder, and major depressive disorder. We  
188 downloaded GWAS summary statistics from the PGC website ([https://pgc.unc.edu/for-  
189 researchers/download-results/](https://pgc.unc.edu/researchers/download-results/)) and manually harmonized the data to our Mendelian  
190 randomization analyses to replicate the FinnGen findings.

## 191 192 **Harmonization of the GWAS summary statistics from the 3 resources**

193 Harmonization of GWAS summary statistics across different models and consortia for various  
194 software is crucial, such as aligning the effect allele and the direction of the effect size. There's  
195 currently no established standard in the field for this process, although some advice has been  
196 proposed<sup>46</sup>. Certain software internally harmonizes data based on the allele frequency of the  
197 effect allele, such as the *TwoSampleMR* package<sup>47</sup> for Mendelian randomization. We outlined the  
198 detailed procedures used to harmonize the GWAS summary data from the three sources.

199 For our UKBB MAE GWAS summary data, we harmonized the effect allele as the  
200 alternative allele from PLINK and A1 from fastGWA. Corresponding allele frequency was also  
201 needed for certain analyses, such as the *TwoSampleMR* package for Mendelian randomization.  
202 Due to privacy considerations, allele frequency information is not publicly available on the  
203 MEDICINE portal. However, it can be provided upon direct email request. P-value, effect sizes  
204 (e.g., BETA value and SE), and sample sizes are harmonized to respective to the effect allele.  
205 The variant identifier is based on the rs ID number, not the chromosome number and position  
206 number combination. All our GWAS summary data are on the human genome build assembly  
207 GRCh37.

208 The FinnGen team has systematically harmonized the GWAS summary data for the 521  
209 DEs involved. The alternative allele serves as the effect allele. The rsID number represents the  
210 SNP; the chromosome number and position are also shared. The data includes P-values, effect  
211 sizes, and allele frequencies for both the alternative and reference alleles. Refer to the FinnGen  
212 documentation for more details: <https://finngen.gitbook.io/documentation/data-description>. We  
213 downloaded the original data and converted the data to GRCh37.

214 PGC did not systematically harmonize the GWAS summary statistics; the available data  
215 information and format depend on each study. **Supplementary eTable 1c** details the 4 DEs (AD,  
216 ADHD, bipolar disorder, and schizophrenia) included after the data filtering procedure. First, we  
217 ensured that the study population comprised individuals of European ancestry and, if necessary,  
218 lifted the data to GRCh37. Secondly, we excluded two studies where the allele frequency is  
219 unavailable because the *TwoSampleMR* package<sup>47</sup> requires this information to harmonize the  
220 exposure and outcome data (e.g., flip the effect allele and effect size). Thirdly, we confirmed that  
221 the GWAS summary statistics didn't overlap with UKBB data. Specifically, the AD GWAS



222 summary data<sup>48</sup> explicitly offered a version that excluded participants from UKBB. In addition,  
223 the original dataset lacked a column for the rsID number. To deal with this, we employed a  
224 mapping approach using the chromosome number and position to the dpSNP database (version  
225 150), which allowed us to obtain the corresponding rsID numbers.

226  
227

## 228 **Method 2: 2024 multi-organ AI endophenotypes**

### 229 **(a): The 2003 patterns of structural covariance of the brain**

230 In our earlier study<sup>12</sup>, we utilized the sopNMF method on an extensive and varied brain imaging  
231 MRI dataset ( $N=50,699$ , including data from UKBB) to generate the multi-scale brain PSCs. The  
232 scale  $C$  ranges from 32 to 1024, progressively increasing by a factor of 2; 11 PSCs vanished  
233 during models.

234 Biologically, the 2003 PSCs represent data-driven structural networks that co-vary across  
235 brain regions and individuals in a coordinated fashion. Mathematically, the sopNMF method is a  
236 stochastic approximation ("deep learning-analogy") constructed and extended based on  
237 opNMF<sup>49,50</sup>. Consider an imaging dataset comprising  $n$  images, each containing  $d$  voxels. We  
238 represent the data as a matrix  $\mathbf{X}$ , where each column corresponds to a flattened image:  $\mathbf{X} =$   
239  $[x_1, x_2, \dots, x_n]$ ,  $\mathbf{X} \in \mathbb{R}_{\geq 0}^{d \times n}$ . The method factorizes  $\mathbf{X}$  into two low-rank matrices  $\mathbf{W} \in \mathbb{R}_{\geq 0}^{d \times r}$  and  
240  $\mathbf{H} \in \mathbb{R}_{\geq 0}^{r \times n}$ , subject to two important constraints: *i*) non-negativity and *ii*) column-wise  
241 orthonormality. More mathematical details can be referred to the original references<sup>12,49,50</sup> and  
242 **Supplementary eMethod 2a.**

243

### 244 **(b): The 9 dimensional neuroimaging endophenotypes of the brain**

245 The nine DNEs captured the neuroanatomical heterogeneity of four brain diseases, including  
246 AD1-2 for AD<sup>32</sup>, ASD1-3 for autism spectrum disorder<sup>51</sup>, LLD1-2 for late-life depression<sup>52</sup>, and  
247 SCZ1-2 for schizophrenia<sup>53</sup>. The underlying AI methodologies involved two different semi-  
248 supervised clustering or representation learning algorithms: Surreal-GAN<sup>54</sup> and HYDRA<sup>55</sup>. Refer  
249 to a review for details of the semi-supervised learning<sup>56</sup>, which primarily seeks the so-called "*l-*  
250 *to-k*" mapping patterns or transformations from reference domains (like healthy controls) to  
251 target domains (such as patients).

252 Surreal-GAN<sup>54</sup> was used to derive AD1-2<sup>32</sup>. It unravels the intrinsic heterogeneity  
253 associated with diseases through a deep representation learning approach. The methodological  
254 innovation, compared to its precentor Smile-GAN<sup>57</sup>, lies in how Surreal-GAN models disease  
255 heterogeneity: it interprets it as a continuous dimensional representation, ensures a consistent  
256 increase in disease severity within each dimension, and permits the simultaneous presence of  
257 multiple dimensions within the same participant without exclusivity. More mathematical details  
258 are presented in **Supplementary eMethod 2b.**

259 HYDRA<sup>55</sup> was employed to derive the other 7 DNEs. It utilizes a widely adopted  
260 discriminative technique, namely support vector machines (SVM), to establish the "*l-to-k*"  
261 mapping. The model extends multiple linear SVMs to the nonlinear domain by piecing them  
262 together. This approach serves the dual purpose of classification and clustering simultaneously.  
263 Specifically, it creates a convex polytope by amalgamating hyperplanes derived from  $k$  linear  
264 SVMs. This polytope separates the healthy control group from the  $k$  subpopulations within the  
265 patient group. Conceptually, each face of this convex polytope can be likened to encoding each  
266 subtype (categorical trait) or dimension (continuous trait), capturing distinctive disease effects  
267 (Refer to **Supplementary eMethod 2c**).

268

269 **(c): The 12 biological age gaps of nine human organ systems**

270 The nine multi-organ BAGs (brain, cardiovascular, eye, hepatic, immune, musculoskeletal,  
271 metabolic, pulmonary, and renal) were derived from a previous study<sup>2</sup> that used AI to predict the  
272 chronological age of healthy individuals without chronic medical conditions: AI-predicted age –  
273 chronological age. Using a 20-fold cross-validation procedure, we applied the model for each  
274 organ system, employing a linear support vector machine. Before training each model iteration,  
275 standardization was applied to measures (excluding categorical variables) within the training set.  
276 The model was solved using sequential minimal optimization with a gap tolerance of 0.001. The  
277 support vector regression settings were adjusted for optimization, adhering to established  
278 principles in the field<sup>58</sup>.

279 Alongside the nine organ BAGs, we previously derived three multimodal brain BAGs  
280 (GM, WM, and FC-IDP) using features from gray matter (GM), white matter (WM), and  
281 functional connectivity (FC) in MRI scans<sup>3</sup>. We systematically compared four machine learning  
282 models: SVR, LASSO regression, multilayer perceptron, and a five-layer neural network. We  
283 employed nested cross-validation (CV) and included an independent test dataset<sup>59</sup> for a fair  
284 comparison across different models and MRI modalities. This process involved an outer loop CV  
285 with 100 repeated random splits: 80% for training and validation and 20% for testing. Within the  
286 inner loop, a 10-fold CV was utilized for hyperparameter tuning. Furthermore, we reserved an  
287 independent test dataset, which was kept unseen until the fine-tuning of the machine learning  
288 models<sup>60</sup> (e.g., hyperparameters for SVR) was completed.

289

290 **Method 3: Genetic analyses based on GWAS summary statistics**

291 **(a): The genetic architecture of the 2024 MAEs and 525 DEs**

292 Primarily, we used SBayesS<sup>61</sup> to estimate three sets of parameters that fully unveil the genetic  
293 architecture of the 2024 MAEs and 525 DEs. SBayesS is an expanded approach capable of  
294 estimating three essential parameters characterizing the genetic architecture of complex traits  
295 through a Bayesian mixed linear model<sup>62</sup>. This method only requires GWAS summary statistics  
296 of the SNPs and LD information from a reference sample. These parameters include SNP-based  
297 heritability ( $h_{SNP}^2$ ), polygenicity ( $\pi$ ), and the relationship between minor allele frequency (MAF)  
298 and effect size ( $S$ ). We used the software pre-computed sparse LD correlation matrix derived from  
299 the European ancestry by Zeng et al.<sup>61</sup>. More mathematical details can be found in the original  
300 paper from Zeng et al.<sup>61</sup>. We ran the *gctb* command<sup>62</sup> using the argument *--sbayes S*, and left all  
301 other arguments by default. When applying SBayesS to the 2025 MAEs and 525 DEs summary  
302 data, we found that 18 DEs failed to converge in the MCMC sampling, which may be due to LD  
303 differences between FinnGen and UKBB samples (the latter was used as the LD reference in  
304 SBayesS).

305 To benchmark different methods used in the field for SNP-based heritability estimates, we  
306 also employed two other methods based on GWAS summary data: *i*) LDSC<sup>28</sup> and *ii*) SumHer<sup>36</sup>.  
307 LDSC relies on the principle that the correlation between SNP effect sizes and linkage  
308 disequilibrium with neighboring SNPs can be used to estimate the proportion of heritability  
309 explained by all SNPs using GWAS summary data. For LDSC, we used the precomputed LD  
310 scores from the 1000 Genomes of European ancestry. All other parameters were set to default in  
311 the software. After merging the GWAS summary statistics, we chose the 1000 Genomes reference  
312 panel for fair comparisons between the two studies and ensured that most SNPs were included in

313 the analyses. For example, for the DE (RX\_PARACETAMOL\_NSAID), after merging with the  
314 reference panel LD, 1,171,361 remained. For the first MAE (C32\_1), 1,092,510 SNPs remained  
315 after the same merging procedure. Furthermore, FinnGen didn't provide the original genotype data;  
316 they only shared the LD information via the LDstore software but did not provide the allele  
317 information. Consequently, we cannot generate in-sample LD scores using the LDSC software.  
318 Finally, a prior investigation<sup>63</sup> showcased the robustness of LDSC concerning the selection of LD  
319 reference panels – multi-ethnic European, Finnish-only, non-Finnish European from 1000  
320 Genomes Phase 3 data, and FINRISK Finnish reference panel – regarding heritability estimates in  
321 four lipid traits within a Finnish population.

322 For SumHer, we used the BLD-LDAK model, as the software suggested. BLD-LDAK  
323 stands for "Bayesian LD-adjusted Kinship," where LD-adjusted kinship refers to the calculation  
324 of genetic relatedness between individuals using information about the correlation of alleles  
325 between nearby SNPs (linkage disequilibrium). We used the software-provided tagging file,  
326 generated from 2000 white British individuals, as a reference panel suggested by the software for  
327 European ancestry groups. The HapMap3 data (<https://www.broadinstitute.org/medical-and-population-genetics/hapmap-3>)  
328 merged with the tested GWAS summary SNPs. Similarly, we  
329 ensured sufficient SNPs remained after merging with the reference panel. All other parameters  
330 were set to default. SumHer differs from LDSC in several ways: *i*) it models inflation  
331 multiplicatively, whereas LDSC uses an additive approach; *ii*) it accounts for uneven LD patterns  
332 and incorporates MAF on SNP effect; and *iii*) it utilizes a restricted maximum likelihood solver  
333 rather than regression to estimate the  $h_{SNP}^2$ .

334  
335 **(b): Genetic correlation:** We used three different methods to compute the MAE-DE pairwise  
336 ( $N=2024 \times 525=1,062,600$ ) genetic correlations ( $r_g$ ): *i*) LDSC<sup>28</sup>, *ii*) GNOVA<sup>37</sup>, and *iii*) HDL<sup>41</sup>.

337 An earlier study<sup>65</sup> highlighted the significance of selecting an appropriate LD score  
338 reference panel for genetic correlation estimates based on summary statistics. We generated the  
339 same reference panel for LD scores across the three software for a fair comparison. For LDSC,  
340 we used the precomputed LD scores from the 1000 Genomes of European ancestry provided by  
341 the software. All other parameters were set by default. To employ GNOVA, we created the LD  
342 scores utilizing the 1000 Genomes of European ancestry using the `--save-ld` argument within the  
343 `gnova.py` script. For HDL, we used the provided scripts from HDL to generate the LD scores  
344 using the same 1000 Genomes of European ancestry  
345 (<https://github.com/zhenin/HDL/wiki/Build-a-reference-panel>).

346 Through our analysis, we found that the three packages have different levels of model  
347 convergence rates, which is critical for future applications as these open-source packages claim  
348 to advance genetic research. In particular, we found that LDSC (1,062,577/1,062,600) and  
349 GNOVA (1,062,600/1,062,600) converged for most of the tested MAE-DE pairs, whereas HDL  
350 failed a substantial proportion of the analyses, leading to only 59,291 out of the 1,062,600 MAE-  
351 DE pairs (refer to the raised issue: <https://github.com/zhenin/HDL/issues/30>). Therefore, in **Fig.**  
352 **2**, we presented common significant results after Bonferroni corrections from the LDSC and  
353 GNOVA, resulting in 133 and 45 significant signals corrected on *i*) the number of MAEs and *ii*)  
354 the number of MAEs and DEs.

355  
356 **(c): Two-sample bidirectional Mendelian randomization:** We employed a bidirectional, two-  
357 sample Mendelian randomization using the *TwoSampleMR* package<sup>47</sup> to infer the causal  
358 relationships between the 2024 MAEs, 521 DEs from FinnGen, and 4 brain DEs from PGC.

359 The forward Mendelian randomization examined causality from the 2024 MAEs to the  
360 525 DEs, while the inverse analysis investigated causality from the 525 DEs to the 2024 MAEs.  
361 The *TwoSampleMR* package<sup>47</sup> applied five different Mendelian randomization methods. We  
362 presented the significant findings after the Bonferroni correction using the inverse variance  
363 weighted (IVW) estimator, verifying that the correction remained significant in at least one of  
364 the other four estimators (Egger, weighted median, simple mode, and weighted mode  
365 estimators). For the significant signals, we performed several sensitivity analyses. First, a  
366 heterogeneity test was performed to check for violating the IV assumptions. Horizontal  
367 pleiotropy was estimated to navigate the violation of the IV's exclusivity assumption<sup>66</sup> using a  
368 funnel plot, single-SNP Mendelian randomization approaches, and Mendelian randomization  
369 Egger estimator. Moreover, the leave-one-out analysis excluded one instrument (SNP) at a time  
370 and assessed the sensitivity of the results to individual SNP.

371 Critically, to enhance transparency and reproducibility, we followed a systematic  
372 procedure guided by the STROBE-MR Statement<sup>67</sup> in conducting all causality analyses. This  
373 comprehensive approach encompassed the selection of exposure and outcome variables,  
374 reporting full sets of statistics, and implementing sensitivity checks to identify potential  
375 violations of underlying assumptions. First, we performed an unbiased quality check on the  
376 GWAS summary statistics. Notably, the absence of population overlapping bias<sup>29</sup> was  
377 confirmed, given that FinnGen and UKBB participants largely represent European ancestry  
378 populations without explicit overlap. For the four PGC DEs, we ensured that no UKBB  
379 participants were included in the GWAS summary data. Furthermore, all GWAS summary  
380 statistics were based on or lifted to GRCh37. Subsequently, we selected the effective exposure  
381 variables by assessing the statistical power of the exposure GWAS summary statistics in terms of  
382 instrumental variables (IVs), ensuring that the number of IVs exceeded 8 before harmonizing the  
383 data. Crucially, the function "*clump\_data*" was applied to the exposure GWAS data, considering  
384 LD. The function "*harmonise\_data*" was then used to harmonize the GWAS summary statistics  
385 of the exposure and outcome variables. This overall resulted in a smaller number (< 525 DEs or  
386 2024 MAEs) of effective exposure/outcome variables in both forward and inverse Mendelian  
387 randomization analyses, as certain GWAS summary data did not have enough IVs.  
388

389 **(d): PRS calculation:** PRS calculation used the GWAS summary statistics from the split-sample  
390 sensitivity analysis from our previous studies<sup>12,3,1,4</sup>. We established PRS weights using split1  
391 GWAS data as the base/training set, while the split2 GWAS summary statistics were used as the  
392 target/testing data. Details of the quality control (QC) procedures are shown in our previous  
393 studies<sup>12,3,1,4</sup>. Following the QC procedures, PRS for the split2 group was computed using PRS-  
394 CS<sup>68</sup>. PRS-CS infers posterior SNP effect sizes under continuous shrinkage priors using GWAS  
395 summary statistics and an LD reference panel (i.e., UKBB reference). The shrinkage parameter  
396 was not set, and the algorithm learned it via a fully Bayesian approach.

397 After determining the optimal model, we applied the model to the entire UKBB sample  
398 (~500k individuals). We then performed a PWAS to link the 2024 PRS-MAEs and 59 additional  
399 phenotypes (**Supplementary eTable 5**) not used to compute the PRS-MAE to avoid circular  
400 bias<sup>69</sup>. The 59 phenotypes include cognitive scores (e.g., fluid intelligence score; Field ID:  
401 20016, mental traits (e.g., fed-up feelings; Filed ID: 1960), and lifestyle factors (e.g., tea intake;  
402 Filed ID: 1488). A linear regression was built considering the following covariates: sex (Field  
403 ID: 31), smoking status (Field ID: 20116), weight (Field ID: 21002), standing height (Field ID:

404 50), waist circumference (Field ID: 48), age at recruitment (Field ID: 21022), and first 40 genetic  
405 principal components (Field ID: 22009).

## 406 Results

### 407 The genetic architecture of the 2024 MAEs and 525 DEs

408 We computed three parameters to fully depict the genetic architecture of the 2024 MAEs  
409 (Method 3a).

410 For the SNP-based heritability ( $h_{SNP}^2$ ), SBayesS<sup>61</sup> obtained the highest  $h_{SNP}^2$  for the 2016  
411 brain MAEs (mean  $\hat{h}_{SNP}^2=0.13$  [0.01, 0.38]), followed by the pulmonary BAG ( $0.16\pm 0.004$ ), the  
412 eye BAG ( $0.14\pm 0.009$ ), the cardiovascular BAG ( $0.12\pm 0.003$ ), the renal BAG ( $0.10\pm 0.003$ ), and  
413 the musculoskeletal BAG ( $0.10\pm 0.003$ ) (Fig. 2a and Supplementary eFile 1). It is worth noting  
414 that SNP-based heritability varies across methods and depends on the input data, i.e., summary  
415 data or individual-level genotype data used in the method<sup>70</sup>. We aimed to benchmark the  
416 summary data-based methods by comparing the results from SBayesS with those of LDSC<sup>28</sup> and  
417 SumHer<sup>36</sup>. Overall, while the estimates from the three methods were highly correlated ( $r=0.97$   
418 between LDSC and SumHer;  $r=0.99$  between SBayesS and SumHer;  $r=0.99$  between SBayesS  
419 and LDSC; Supplementary eFigure 1), SumHer ( $0.23\pm 0.14$ ) generally yielded larger  $h_{SNP}^2$   
420 estimates than both LDSC ( $0.16\pm 0.10$ ) and SBayesS ( $0.13\pm 0.08$ ) (Supplementary eFile 1). This  
421 discrepancy across different data types (i.e., summary data vs. individual genotype data) and  
422 methods (e.g., LDSC vs. SBayesS) has been previously observed and compared in the literature,  
423 where the authors evaluated multiple methods designed for individual genotype data<sup>70</sup>. While we  
424 observed some differences in effect size magnitude across our three summary-data methods, the  
425 estimates remain highly correlated, ensuring internal validity within each method. However, we  
426 do not recommend directly comparing the numeric estimates across methods based on magnitude  
427 alone. Instead, greater emphasis should be placed on the confidence interval of standard errors of  
428 the estimates. We present the  $h_{SNP}^2$  estimate of the 525 DEs and 2024 MAEs in Supplementary  
429 eFigure 2. Supplementary eFile 2 presents the results of the 525 DEs. For the 525 DEs, we  
430 converted the  $h_{SNP}^2$  estimates from the observed scales to the liability scales, following the  
431 recommendations of Ojavee et al<sup>71</sup>. It's important to clarify that we did not intend to compare the  
432  $h_{SNP}^2$  estimates of the two data sources due to differences in genotype coverage, sample sizes,  
433 allele frequencies, and other factors.


434 We then computed the natural selection signature ( $S$ ) for the 2024 MAEs. The metabolic  
435 BAG showed a strong negative selection ( $S=-0.82\pm 0.10$ ), followed by the pulmonary BAG ( $S=-$   
436  $0.79\pm 0.05$ ), the hepatic BAG ( $S=-0.74\pm 0.09$ ), the renal BAG ( $S=-0.68\pm 0.08$ ), and the immune  
437 BAG ( $S=-0.66\pm 0.11$ ). For the brain MAEs ( $S=-0.33$  [-1, 0.43]), the brain BAG and ( $S=-$   
438  $0.70\pm 0.12$ ) the subtype (ASD1) for autism spectrum disorder<sup>51</sup> ( $S=-0.90\pm 0.11$ ) showed strong  
439 negative selection effects (Fig. 2b and Supplementary eFile 3).

440 Finally, we calculated the polygenicity ( $\pi$ ) for the 2024 MAEs. We found that brain  
441 MAEs ( $0.040$  [0.003, 0.072]) showed higher polygenicity than other organ systems (t-  
442 statistic=5.75; P-value= $1.03\times 10^{-8}$ ), followed by the pulmonary BAG ( $0.018\pm 0.001$ ), the  
443 musculoskeletal BAG ( $0.013\pm 0.001$ ), and the cardiovascular BAG ( $0.011\pm 0.001$ ) (Fig. 2c and  
444 Supplementary eFile 4). The PSC (C128\_115: [https://labs-](https://labs-laboratory.com/bridgeport/MuSIC/C128_115)  
445 [laboratory.com/bridgeport/MuSIC/C128\\_115](https://labs-laboratory.com/bridgeport/MuSIC/C128_115)) showed the highest polygenicity estimate  
446 ( $0.072\pm 0.002$ ).

### 448 Potential evidence for the endophenotype hypothesis

449 Previous studies<sup>72,73</sup> have found supporting evidence for the endophenotype hypothesis<sup>14,15</sup> using  
450 traditional brain map-based signatures, showing that more genetic variants are associated with

451 disease endpoints than imaging-derived signatures (i.e., endophenotypes). Of note, considering  
 452 genetic differences between FinnGen and UKBB samples, SBayesS with the UKBB as LD  
 453 reference may give biased estimates of  $S$  and  $\pi$  (LD from FinnGen not fully available; **Method**  
 454 **3a**). Therefore, we used the GWAS summary data for PGC schizophrenia (SCZ<sup>74</sup>) and two  
 455 subtypes of SCZ (SCZ1 and SCZ2<sup>4</sup>) from our UKBB analysis to demonstrate this. The  
 456 advantage of using PGC data is that the GWAS summary statistics are better powered (large  
 457 sample sizes), and the data were from European ancestry groups across different countries. A  
 458 data harmonization procedure is outlined in **Supplementary eMethod 1** to ensure a fair  
 459 comparison of these estimates, which led to the utilization of a common set of SNPs and linkage  
 460 disequilibrium information for computing the  $S$  and  $\pi$  parameters. Our results showed that MAE-  
 461 SCZ1 ( $\pi=0.048\pm 0.002$ ;  $S=-0.61\pm 0.09$ ) and MAE-SCZ2 ( $\pi=0.047\pm 0.002$ ;  $S=-0.54\pm 0.12$ ) had  
 462 lower polygenicity signals and weaker negative selection effects than PGC-SCZ  
 463 ( $\pi=0.055\pm 0.003$ ;  $S=-0.82\pm 0.04$ ) (**Fig. 2d**). **Supplementary eFigure 3** shows the Manhattan plot  
 464 of the harmonized summary data for MAE-SCZ1, MAE-SCZ2, and PGC-SCZ. These findings  
 465 potentially support the endophenotype hypothesis<sup>75</sup>, which suggests that intermediate phenotypes  
 466 (e.g., SCZ subtype MAEs) reside inside the causal pathway from genetics to exo-phenotypes  
 467 (e.g., SCZ binary diagnosis), making them closer to the underlying etiology<sup>72,73</sup>.



468 **Figure 2: The genetic architecture of the 2024 MAEs**  
 469 Three parameters are estimated by SBayesS to delineate the genetic architecture of the 2024  
 470 MAEs, including (a) the SNP-based heritability ( $h^2_{SNP}$ ), (b) the relationship between MAF and  
 471 effect size ( $S$ ), and (c) polygenicity ( $\pi$ ). (d) We compared the  $\pi$  and  $S$  parameters using  
 472 harmonized GWAS summary data for two AI- and imaging-derived subtypes (MAE-SCZ1 and  
 473 MAE-SCZ2) and PGC-SCZ.

474 MAE-SCZ2<sup>4</sup>) from UKBB and the disease endpoint of schizophrenia (PGC-SCZ<sup>74</sup>) from PGC.  
475 FinnGen data was not used due to bias stemming from the unavailability of FinnGen-specific  
476 linkage disequilibrium data (**Supplementary eMethod 1**). We present the distribution of the  
477 estimated parameters for the 2016 brain MAEs using a violin plot; the mean value is denoted by  
478 the black horizontal line. These results should be interpreted cautiously for comparative purposes  
479 due to limitations stemming from the lack of individual genotype data from FinnGen and PGC,  
480 differing linkage disequilibrium structures, and varying sample sizes.

481


### 482 **The genetic correlation shows organ-specific and cross-organ associations**

483 We found 132 (P-value < 0.05/2024) and 45 (P-value < 0.05/2024/525) commonly significant  
484 positive genetic correlations ( $r_g$ ) after applying two levels of Bonferroni correction (**Fig. 3**) for  
485 the LDSC<sup>28</sup> and GNOVA<sup>37</sup> methods (**Method 3b, Supplementary eFile 5, and Supplementary**  
486 **eTable 2**). We noted that HDL encountered convergence issues with the models, as detailed in  
487 **Method 3b**.

488 Between these methods, the magnitude of the genetic correlations for the significant  
489 signals for both methods differed: mean  $\hat{r}_g=0.24[-0.40\sim0.52]$  with 213 significant signals for  
490 LDSC, mean  $\hat{r}_g=0.17[-0.30\sim0.62]$  for GNOVA with 428 significant signals (**Fig. 2**). The three  
491 sets of converged estimates showed a strong correlation:  $r=0.77$  (P-value< $1\times10^{-10}$ ;  $N=1,062,577$ )  
492 between LDSC and GNOVA,  $r=0.81$  (P-value< $1\times10^{-10}$ ;  $N=59,289$ ) between LDSC and HDL,  
493 and  $r=0.82$  (P-value< $1\times10^{-10}$ ;  $N=59,289$ ) between GNOVA and HDL. **Supplementary eFigure**  
494 **4** shows the correlation of the three sets of estimates.

495 Within the significant signals identified, we observed *i*) organ-specific associations, in  
496 which the MAE showed a genetic association with the DE originating from the respective organ  
497 system, and *ii*) cross-organ connections, in which the MAE and DE were primarily involved  
498 from different organ systems. For example, two brain PSCs showed significant negative genetic  
499 correlations with BIP from PGC (C512\_368 vs. BIP:  $-0.16\pm0.03$ ; C1024\_114 vs. BIP: -  
500  $0.15\pm0.03$ ). At a less stringent level, the brain MAEs were also genetically associated with DEs  
501 from other organ systems, including the positive correlation between C1024\_808 and obesity  
502 (E4\_OBESITY:  $r_g=0.17\pm0.13$ ). The cardiovascular BAG was positively correlated with several  
503 DEs related to the cardiovascular system, including ischemic heart disease (I9\_IHD:  
504  $r_g=0.26\pm0.03$ ), coronary heart disease (I9\_HEARTFAIL\_AND\_CHD:  $r_g=0.26\pm0.03$ ), angina  
505 (I9\_ANGINA:  $r_g=0.25\pm0.03$ ) and atrial fibrillation (I9\_Af:  $r_g=0.22\pm0.04$ ). Likewise, the  
506 pulmonary BAG was positively associated with multiple DEs related to the lung and respiratory  
507 system, including chronic obstructive pulmonary disease (COPD\_EARLY:  $r_g=0.47\pm0.04$ ) and  
508 various forms of asthma (ASTHMA\_NAS:  $r_g=0.43\pm0.04$ ). Cross-organ connections were  
509 established, such as between the pulmonary BAG and substance abuse  
510 (KRA\_PSY\_SUBSTANCE\_EXMORE:  $r_g=0.20\pm0.03$ ) and hypertension (I9\_HYPTENS:  
511  $r_g=0.17\pm0.03$ ). Lastly, the metabolic BAG was largely linked to different forms of diabetes  
512 (T2D:  $r_g=0.40\pm0.04$ ).





513  
 514 **Figure 3: Genetic correlation between the 2024 MAEs and 525 DEs**  
 515 The significant genetic correlation estimates ( $r_g$ ) between 2024 MAEs and 525 DEs are depicted,  
 516 considering two levels of corrections for multiple comparisons, considering the relatively smaller  
 517 sample sizes (<40,000) for brain MAEs compared to other organ MAEs (>100,000). Initially, we


518 reveal significant results shared between LDSC and GNOVA, employing Bonferroni correction  
519 based solely on the number of MAEs (P-value<0.05/2024), uncovering 133 MAE-AE pairs.  
520 Subsequently, a stricter correction based on both the number of MAEs and DEs is applied,  
521 leading to 45 unique MAE-AE pairs marked as red squares; the numeric results are displayed  
522 using results from LDSC. The genetic correlation for non-significant results was set to 0 for  
523 visualization purposes. For the MAEs, readers can explore the BRIDGEPORT portal for a visual  
524 representation of the 2003 brain PSCs (e.g., C256\_225: [https://labs-  
525 laboratory.com/bridgeport/MuSIC/C256\\_225](https://labs-laboratory.com/bridgeport/MuSIC/C256_225)) and the other BAGs at the MEDICINE portal:  
526 <https://labs-laboratory.com/medicine>.

### 527 528 **The brain, cardiovascular, and pulmonary MAEs are causally linked to DEs of multiple** 529 **organ systems**

530 Employing five distinct two-sample Mendelian randomization estimators, we identified 39 (P-  
531 value<0.05/633) and 15 (P-value<0.05/633/524) significant causal relationships, directed from  
532 the MAE to DE, that withstood the Bonferroni correction at two different levels of rigors, as per  
533 the inverse variance weighted (IVW) estimator and at least one of the other four estimators  
534 (**Method 3c** and **Supplementary eTable 3**).

535 Within the 15 significant causal relationships, the brain MAEs showed causal  
536 connections with DEs from the brain, as well as DEs from other organ systems. For example, the  
537 brain PSC (C1024\_598) was causally linked to SCZ from PGC [P-value=9.89x10<sup>-8</sup>; OR (95%  
538 CI)=0.69 (0.59, 0.79); the number of IVs=7]. C1024\_684 was causally linked to Ventral hernia  
539 from FinnGen [K11\_VENTHER: P-value=1.09x10<sup>-7</sup>; OR (95% CI)=1.43 (1.25, 1.63); the  
540 number of IVs=18]. The pulmonary BAG was causally linked to multiple DEs related to the  
541 pulmonary system, including chronic obstructive pulmonary disease (COPD) [J10\_COPD: P-  
542 value=2.70x10<sup>-20</sup>; OR (95% CI)=1.77 (1.56, 2.00); the number of IVs=59] and asthma  
543 [ASTHMA\_PNEUMONIA: P-value=1.51x10<sup>-14</sup>; OR (95% CI)=1.67 (1.41, 1.96); the number of  
544 IVs=59]. The cardiovascular BAG was causally linked to ischemic heart disease (IHD)  
545 [ASTHMA\_PNEUMONIA: P-value=1.09x10<sup>-7</sup>; OR (95% CI)=1.64 (1.36, 1.96); the number of  
546 IVs=37] (**Fig. 4**). **Supplementary eFile 6** presents the full set of results for the 521 FinnGen  
547 DEs and 4 PGC DEs. Mendelian randomization relies on stringent assumptions that can  
548 sometimes be violated. We showcased comprehensive sensitivity analyses for the significant  
549 signal from the cardiovascular BAG to ischemic heart disease (I9\_IHD; **Supplementary eNote 1**  
550 and **Supplementary eFigure 5**).

551  
552  
553




554  
 555 **Figure 4: Causal relationship from the 2024 MAEs to the 525 DEs**  
 556 The causal relationship from the 2024 MAEs to the 525 DEs revealed 39 significant MAE-DE  
 557 pairs, involving 633 MAEs as effective exposure variables (>8 instrumental variables before  
 558 harmonization) and 525 DEs as outcomes. Bonferroni correction was applied to identify  
 559 potential significant causal signals based on *i*) the 633 MAEs (P-value<0.05/633) and *ii*) the 633  
 560 MAEs and 525 DEs (P-value<0.05/633/524, denoted by the 15 red rectangles). Furthermore, we  
 561 verified that the statistical significance attained for the IVW estimator was consistent and  
 562 persisted across at least one of the other four Mendelian randomization estimators (Egger,  
 563 weighted median, simple mode, and weighted mode estimators). For visualization purposes, the  
 564 odds ratios for non-significant results were set to 1 and were left blank. For the MAEs, readers  
 565 can explore the BRIDGEPORT portal for a visual representation of the 2003 brain PSCs (e.g.,  
 566 C32\_4: [https://labs-laboratory.com/bridgeport/MuSIC/C32\\_4](https://labs-laboratory.com/bridgeport/MuSIC/C32_4)) and the other BAGs at the  
 567 MEDICINE portal: <https://labs-laboratory.com/medicine>. It is crucial to approach the  
 568 interpretation of these potential causal relationships with caution despite our thorough efforts in  
 569 conducting multiple sensitivity checks to assess any potential violations of underlying  
 570 assumptions.

571  
 572 **The DEs involving Alzheimer’s disease, diabetes, asthma, and hypertension exert causal**  
 573 **effects on multi-organ MAEs**

574 We then tested the inverse causality by employing the DEs as exposure and MAEs as outcome  
 575 variables. We identified 47 (P-value<0.05/787) and 23 (P-value<0.05/787/214) significant causal  
 576 relationships, directed from the DE to MAE, that survived the Bonferroni correction at two  
 577 different levels of rigors (**Method 3c** and **Supplementary eTable 4**).

578 Within the 23 significant causal relationships (P-value<0.05/787/214), various forms of  
 579 Alzheimer’s disease were linked to the brain MAEs, including the brain BAG [G6\_AD\_WIDE:  
 580 P-value=3.03x10<sup>-7</sup>; OR (95% CI)=1.10 (1.06, 1.13); the number of IVs=8] and metabolic BAG  
 581 [G6\_AD\_WIDE: P-value=3.03x10<sup>-7</sup>; OR (95% CI)=1.07 (1.04, 1.09); the number of IVs=8].  
 582 Type 1 diabetes (E4\_DM1NASCOMP) was also causally linked to multiple brain PSCs. In  
 583 addition, the cardiovascular BAG was causally linked to multiple heart diseases, including  
 584 hypertension [I9\_HYPTENS: P-value=4.67x10<sup>-31</sup>; OR (95% CI)=1.23 (1.19, 1.27); the number  
 585 of IVs=110]. Several forms of asthma were causally linked to the pulmonary BAG, such as

586 allergic asthma [ALLERG\_ASTHMA: P-value=2.38x10<sup>-9</sup>; OR (95% CI)=1.09 (1.06, 1.13); the  
 587 number of IVs=14]. Finally, obesity was also linked to the renal BAG [E4\_OBESITY: P-  
 588 value=2.74x10<sup>-8</sup>; OR (95% CI)=1.11 (1.07, 1.15); the number of IVs=19] (**Fig. 5**).  
 589 **Supplementary eFile 7** presents the full set of results for the 521 FinnGen DEs and 4 PGC DEs.  
 590



591 **Figure 5: Causal relationship from the 525 DEs to the 2024 MAEs**  
 592 The causal relationship from the 525 MAEs to the 2024 DEs revealed 47 significant DE-MAE  
 593 pairs, involving 214 DEs as effective exposure variables (>8 instrumental variables before  
 594 harmonization) and 787 DEs as effective outcomes after quality checks. Bonferroni correction  
 595 was applied to identify potential significant causal signals based on *i*) the 787 MAEs (P-  
 596 value<0.05/787) and *ii*) the 787 MAEs and 214 DEs (P-value<0.05/787/214, denoted by the 23  
 597 red rectangles). Furthermore, we verified that the statistical significance attained for the IVW  
 598 estimator was consistent and persisted across at least one of the other four Mendelian  
 599 randomization estimators (Egger, weighted median, simple mode, and weighted mode  
 600 estimators). For visualization purposes, the odds ratios for non-significant results were set to 1  
 601 and were left blank. For the MAEs, readers can explore the BRIDGEPORT portal for a visual  
 602 representation of the 2003 brain PSCs (e.g., C128\_13: [https://labs-](https://labs-laboratory.com/bridgeport/MuSIC/C128_13)  
 603 [laboratory.com/bridgeport/MuSIC/C128\\_13](https://labs-laboratory.com/bridgeport/MuSIC/C128_13)) and the other BAGs at the MEDICINE portal:  
 604 <https://labs-laboratory.com/medicine>. It is crucial to approach the interpretation of these potential  
 605

606 causal relationships with caution despite our thorough efforts in conducting multiple sensitivity  
607 checks to assess any potential violations of underlying assumptions.

608


### 609 **The polygenic risk scores of the 2024 MAEs**

610 Using the PRS-CS<sup>68</sup> method, we derived the PRS of the 2024 MAEs. We found that the 1799  
611 MAEs could significantly (P-value<0.05/2024) predict the phenotypic BAGs in the test/target  
612 data (split2 GWAS; detailed in **Method 3d**). Among these, 1791 brain MAEs resulted in  
613 significant incremental  $R^2$  ranging from 0.11% to 10.70% to predict the phenotype of interest.  
614 For example, the PSC (C1024\_593 for part of the cerebellum: [https://labs-](https://labs-laboratory.com/bridgeport/MuSIC/C1024_593)  
615 [laboratory.com/bridgeport/MuSIC/C1024\\_593](https://labs-laboratory.com/bridgeport/MuSIC/C1024_593)) showed an incremental of  $R^2$  10.70%. The renal  
616 BAG showed an incremental  $R^2$  of 5.92%, followed by the metabolic ( $R^2 = 5.67%$ ) and  
617 pulmonary BAG ( $R^2 = 3.86%$ ) (**Fig. 5a** and (**Supplementary eFile 8**)).

618 We then applied the model to the entire UKBB population and performed a PRS-wide  
619 association study (PWAS), where the 2024 PRS-MAEs were linked to the 59 phenotypes that  
620 were not initially used to compute the respective PRS, to avoid the circular bias<sup>69</sup>  
621 (**Supplementary eTable 5**). Refer to **Method 3d** for details. We found 388 significant  
622 associations (P-value<0.05/2024/59) between 7 PRS-MAEs and 41 phenotypes. Among these,  
623 PSC C32\_1 showed the most associations (94%); the lifestyle factor for only fish intake (Field  
624 ID: 16) was highly linked to multiple PRS-MAEs (16%). These results were expected because  
625 the 59 phenotypes (e.g., cognitive and mental traits) are primarily linked to the brain, and  
626 lifestyle factors were largely linked to multiple organ systems (**Fig. 5b** and **Supplementary**  
627 **eFile 9**). All derived PRS will be returned to UKBB and made available to the community.

628

629



630  
 631 **Figure 6: The polygenic risk score of the 2024 MAEs and PWAS**  
 632 (a) The incremental  $R^2$  of the PRS derived by PRC-CS to predict the 2024 MAEs in the  
 633 target/test data (i.e., the split2 GWAS). The y-axis indicates the proportions of phenotypic  
 634 variation that the PRS can significantly and additionally explain (i.e., incremental  $R^2$ ). The x-axis  
 635 lists the 8 organ systems. For the brain, we showed the PRS distribution of the significant results  
 636 from the 1791 brain PRS-MAEs; the other organ systems only have one PRS-MAE. (b) The  
 637 PWAS links the PRS-MAEs to the 59 additional phenotypes not used to compute the PRS-MAE  
 638 in the entire UKBB sample (P-value<0.05/2024/59).  
 639

## 640 Discussion

641 This study expands previously established genetic atlases<sup>76,35</sup> by integrating AI-derived  
642 endophenotypes via the 2024 MAEs within the multi-organ framework solely through GWAS  
643 summary statistics. We demonstrate a promising avenue for advancing imaging genetic research  
644 in two key aspects: *i*) integrating AI in imaging genetics and *ii*) exploring human aging and  
645 disease through a multi-organ perspective.

646 By comprehensively depicting the genetic architecture of the 2024 MAEs, we showcased  
647 that AI endophenotypes supported the endophenotype hypothesis<sup>14,15</sup>, in which they showed  
648 lower polygenicity and weaker negative selection effects than the disease diagnosis. First, it may  
649 suggest that these intermediate phenotypes exist along the causal pathway, bridging the gap  
650 between underlying genetics and "exo-phenotypes" like cognitive decline or disease diagnoses in  
651 case/control studies, thus positioned closer to the core etiology and pathology. Secondly, many  
652 of these 2024 MAEs originated from *in vivo* imaging methodologies like magnetic resonance  
653 imaging (MRI). Consequently, they tend to exhibit reduced noise levels (i.e., a higher SNR) in  
654 capturing disease-related effects and are less susceptible to biases, such as misclassification<sup>77</sup>,  
655 case/control-covariate sample bias (e.g., studies matching comorbidities and other factors), and  
656 imbalanced case/control ratios, as evidenced in many GWASs in FinnGen. Especially for the  
657 former, binary traits have a threshold for disease classification, leading to the dichotomization of  
658 individuals into affected and unaffected categories. Thirdly, the 525 DEs often represent  
659 complex diseases highly influenced by multiple genetic and environmental factors. Their  
660 multifaceted nature, involving numerous genes with modest effects and environmental  
661 interactions<sup>78</sup>, can lead to a higher vulnerability to disease onset and clinical symptoms.  
662 Consistent with this observation, we previously also found that one AI- and imaging-derived  
663 subtype of Alzheimer's disease<sup>32</sup> (AD1), but not the binary disease diagnosis, was genetically  
664 correlated with brain age (GM- and WM-BAG)<sup>3</sup>.

665 We observed that brain MAEs were overall more polygenic than MAEs from other organ  
666 systems. Brain disorders are highly polygenic<sup>79</sup>. First, the brain is a highly complex organ with  
667 intricate functions, and disorders affecting it are likely influenced by a larger number of genetic  
668 variants<sup>12,80</sup>. Second, many brain disorders are multifaceted, involving various aspects of brain  
669 structure, function, and connectivity, which can be influenced by various genetic factors<sup>19</sup>.  
670 Additionally, the brain regulates many physiological processes throughout the body, so  
671 disruptions in its function can have widespread effects, potentially involving interactions with  
672 multiple organ systems<sup>1</sup>. In addition, we found that most of the brain MAEs showed negative  
673 selection signatures, including the 9 disease subtype DNEs and 4 brain BAGs; some of the brain  
674 PSCs showed a positive *S* estimate (e.g., for the occipital lobe and subcortical structure,  
675  $S=0.31\pm 0.09$ : [https://labs-laboratory.com/bridgeport/MuSIC/C32\\_18](https://labs-laboratory.com/bridgeport/MuSIC/C32_18)). The anticipated negative  
676 selection signatures of biological age across multiple organs and disease subtypes are expected to  
677 align with our prior findings, which revealed pervasive signatures of natural selection across a  
678 range of complex human traits and functional genomic categories. This negative selection  
679 signature prevents mutations with large deleterious effects from becoming frequent in the  
680 population<sup>81</sup>. The positive selection signatures identified in certain brain PSCs may suggest that  
681 positive selection may also play a role in shaping the genetic architecture of brain structural  
682 networks.

683 In previous studies on estimating SNP-based heritability, Elliott et al.<sup>19</sup> used the SBAT  
684 (Sparse Bayesian Association Test) method with summary-level data to report heritability  
685 estimates for over 3,000 conventional imaging-derived phenotypes. For structural MRI-derived

686 phenotypes – comparable to those derived from T1-weighted MRI in our 2,003 brain PSCs<sup>12</sup> –  
687 they reported estimates of similar magnitude, if not lower for the mean, than ours. A potential  
688 reason for this difference is that we used the GCTA method<sup>82</sup> with individual-level genetic data,  
689 which tends to provide more precise estimates in particular regarding LD patterns. This was  
690 further confirmed by Zhao et al., who also applied the GCTA method to estimate the heritability  
691 of these imaging-derived phenotypes<sup>83</sup>. Compared to previous studies using SBayesS to estimate  
692 polygenicity and selection signatures, Zeng and colleagues conducted two studies assessing these  
693 parameters across various traits, including disease endpoints (e.g., schizophrenia), cognitive  
694 traits (e.g., intelligence), and anthropometric (e.g., BMI) traits. Notably, in Zeng et al.<sup>61</sup>, the  
695 strongest negative selection signature was reported for dyslipidemia ( $S=-0.77$ ), which we  
696 compare to our metabolic BAG in **Fig. 2b**.

697 The MUTATE atlas uncovered both established and previously undiscovered interactions  
698 concerning human systemic diseases within individual organs and across diverse organ systems.  
699 For example, within the cardiovascular system, the AI-derived MAE, cardiovascular BAG  
700 showed both substantial genetic correlation (**Fig. 2**) and bi-directional causality (**Fig. 3 and 4**)  
701 with multiple heart diseases, such as ischaemic heart disease<sup>84</sup>, heart failure<sup>85</sup>, and atrial  
702 fibrillation<sup>86</sup>. Similarly, pulmonary BAG was also causally linked to multiple diseases related to  
703 the lung and respiratory system, including COPD<sup>87</sup> and various forms of asthma<sup>88</sup>. Another  
704 organ-specific connection was observed in neurologic diseases, encompassing conditions such as  
705 AD<sup>89</sup> and various mental disorders<sup>90</sup> linked to several MAEs associated with the brain, notably  
706 several PSCs and WM-BAG. Cross-organ interplay was evidenced for several novel  
707 connections. For instance, the brain PSCs exhibited causal connections to conditions extending  
708 beyond the brain, such as ventral hernia and vein diseases, as well as systemic conditions, like  
709 various forms of diabetes affecting the entire body. In contrast, AD appears to causally impact  
710 multiple BAGs across various human organ systems, including the renal, immune, and metabolic  
711 systems. It's widely recognized that AD, being a complex condition, triggers detrimental effects  
712 that influence several human organ systems<sup>89,91</sup>. Our previous study used imaging genetics to  
713 investigate this multi-organ involvement along the disease continuum<sup>92</sup>. These results highlight  
714 the clinical relevance and interpretation of these AI endophenotypes to quantify individual-level  
715 organ health.

716 Emphasizing preventative strategies for specific chronic diseases is crucial to enhancing  
717 overall multi-organ health. Our MAEs present opportunities as novel instruments for selecting  
718 populations in clinical trials and facilitating therapeutic development. For example, one potential  
719 future avenue is to investigate whether these AI-driven disease subtype (e.g., AD DNEs) can be  
720 used to more effectively stratify patients for future AD clinical trial development and drug effect  
721 monitor. The hypothesis is that specific subtypes of AD patients may exhibit a better response to  
722 anti-amyloid therapies, with neuroimaging-derived MAEs serving as a selection tool to identify  
723 patients who are most likely to benefit, characterized by a high-risk, high-benefit profile. AD and  
724 various forms of diabetes exemplify disease endpoints significantly impacting multiple human  
725 organ systems. AD stands as the leading cause of dementia in older adults, presenting a  
726 persistent challenge in medicine despite numerous pharmacotherapeutic clinical trials. These  
727 trials have included interventions, such as anti-amyloid drugs<sup>93,94</sup> and anti-tau drugs.<sup>95</sup> The  
728 complexity and multifaceted nature of the underlying neuropathological processes may account  
729 for the lack of effective treatments. We call on the scientific community to embrace various  
730 mechanistic hypotheses to elucidate AD pathogenesis beyond amyloid and tau<sup>96,97</sup>. Likewise, the  
731 complexity of diabetes, with its various contributing factors, renders prevention challenging<sup>98</sup>.



732 Moreover, diabetes often coexists with other chronic conditions affecting multiple organ  
733 systems, such as cardiovascular diseases, hypertension, and dyslipidemia<sup>99</sup>. Successful  
734 prevention strategies require a holistic approach, encompassing lifestyle adjustments, education,  
735 healthcare access, and societal considerations.

736

## 737 **Limitation**

738 This study presents several limitations. Primarily, our analyses were centered solely on GWAS  
739 summary statistics derived from individuals of European ancestries. Future investigations should  
740 extend these findings to diverse ethnic groups, particularly those that are underrepresented, to  
741 ascertain broader applicability. This necessitates the research community's commitment to  
742 embracing open science in AI and genetics. Secondly, the computational genomics statistical  
743 methods utilized in this research rely on several underlying statistical assumptions, which could  
744 potentially be violated and introduce bias. We mitigated bias by employing multiple  
745 methodologies to compute heritability, genetic correlation, and causality to address this concern.  
746 Additionally, we conducted thorough sensitivity checks, and the detailed results are provided  
747 accordingly. Additionally, our analysis was limited by the lack of individual-level genotype data  
748 from FinnGen and PGC, highlighting the need for future studies utilizing individual-level data to  
749 validate our empirical findings. Finally, our study recognizes a tradeoff between clinical  
750 interpretability and the detection of genetic associations when using AI-derived phenotypes.

751

## 752 **Outlook**

753 In summary, we introduced the MUTATE genetic atlas to comprehensively comprehend the  
754 genetic architecture of AI endophenotypes and chronic diseases in multi-organ science. This  
755 investigation underscores the potential of integrating AI into genetic research and supports a  
756 comprehensive approach to investigating human diseases within a multi-organ paradigm.

757

## 758 **Data Availability**

759 The results of the MUTATE atlas are disseminated at the MUTATE knowledge portal:  
760 <https://labs-laboratory.com/mutate>. The GWAS summary statistics for the 2024 MAEs can be  
761 accessed publicly through the MEDICINE knowledge portal: [https://labs-](https://labs-laboratory.com/medicine)  
762 [laboratory.com/medicine](https://labs-laboratory.com/medicine) and the BRIDGEPORT knowledge portal: [https://labs-](https://labs-laboratory.com/bridgeport)  
763 [laboratory.com/bridgeport](https://labs-laboratory.com/bridgeport). The GWAS summary statistics for the 521 DEs from FinnGen are  
764 publicly available at: <https://finngen.gitbook.io/documentation/v/r9/>. The GWAS summary  
765 statistics for the 4 DEs from PGC are publicly available at: [https://pgc.unc.edu/for-](https://pgc.unc.edu/for-researchers/download-results/)  
766 [researchers/download-results/](https://pgc.unc.edu/for-researchers/download-results/). The study used only GWAS summary statistics rather than  
767 individual-level data from the UK Biobank. However, the 2024 MAE GWAS data was initially  
768 derived from previous studies conducted under Application Numbers 35148 and 60698 from the  
769 UK Biobank.

## 770 **Code Availability**

771 The software and resources used in this study are all publicly available:

- 772 • *GCTB*: <https://cnsgenomics.com/software/gctb/#Overview>, SNP-based heritability,  
773 polygenicity, and MAF/effect size ratio
- 774 • *LDSC*: <https://github.com/bulik/ldsc>, SNP-based heritability and genetic correlation
- 775 • *SumHer*: <https://dougsspeed.com/sumher/>, SNP-based heritability
- 776 • *GNOVA*: <https://github.com/xtonyjiang/GNOVA>, genetic correlation
- 777 • *HDL*: <https://github.com/zhenin/HDL>, genetic correlation
- 778 • *TwoSampleMR*: <https://mrcieu.github.io/TwoSampleMR/index.html>, Mendelian  
779 randomization
- 780 • PRS-CS: <https://github.com/getian107/PRScs>, PRS
- 781 • Surreal-GAN: <https://github.com/zhijian-yang/SurrealGAN>, to derive AD1 and AD2
- 782 • HYDRA: <https://github.com/anbai106/mlni>, to derive LLD1-2, SCZ1-2, ASD1-3, and  
783 GM-, WM-, FC-BAG
- 784 • sopNMF: <https://github.com/anbai106/SOPNMF>, to derive the 2003 brain PSCs
- 785 • BioAge: <https://github.com/yetianmed/BioAge>, to derive the 9 multi-organ BAGs
- 786

787 **Competing Interests**

788 None

789

790 **Authors' contributions**

791 Dr. Wen has full access to all the study data and is responsible for its integrity and accuracy.

792 *Study concept and design:* W.J

793 *Acquisition, analysis, or interpretation of data:* W.J

794 *Drafting of the manuscript:* W.J

795 *Critical revision of the manuscript for important intellectual content:* All authors

796 *Statistical analysis:* W.J

797 **References**

798

## 799 **Acknowledgment**

800 The MULTI consortium (J.W) aims to integrate multi-organ and multi-omics biomedical data to  
801 advance our understanding of human aging and disease mechanisms. The current study does not  
802 use any individual data. The 2024 MAE GWAS summary data were derived from UK Biobank  
803 under Application numbers: 647044, 35148, and 60698. We sincerely thank the UK Biobank  
804 (<https://www.ukbiobank.ac.uk/>), FinnGen (<https://www.finngen.fi/en>), and PGC  
805 (<https://pgc.unc.edu/>) team for their invaluable contribution to advancing clinical research in our  
806 field.